Cargando…

The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats

The distribution, clearance, and bioavailability of (2S,6S)-hydroxynorketamine has been studied in the Wistar rat. The plasma and brain tissue concentrations over time of (2S,6S)-hydroxynorketamine were determined after intravenous (20 mg/kg) and oral (20 mg/kg) administration of (2S,6S)-hydroxynork...

Descripción completa

Detalles Bibliográficos
Autores principales: Moaddel, Ruin, Sanghvi, Mitesh, Dossou, Katina Sourou Sylvestre, Ramamoorthy, Anuradha, Green, Carol, Bupp, James, Swezey, Robert, O’Loughlin, Kathleen, Wainer, Irving W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492732/
https://www.ncbi.nlm.nih.gov/pubmed/26171236
http://dx.doi.org/10.1002/prp2.157
_version_ 1782379809511309312
author Moaddel, Ruin
Sanghvi, Mitesh
Dossou, Katina Sourou Sylvestre
Ramamoorthy, Anuradha
Green, Carol
Bupp, James
Swezey, Robert
O’Loughlin, Kathleen
Wainer, Irving W
author_facet Moaddel, Ruin
Sanghvi, Mitesh
Dossou, Katina Sourou Sylvestre
Ramamoorthy, Anuradha
Green, Carol
Bupp, James
Swezey, Robert
O’Loughlin, Kathleen
Wainer, Irving W
author_sort Moaddel, Ruin
collection PubMed
description The distribution, clearance, and bioavailability of (2S,6S)-hydroxynorketamine has been studied in the Wistar rat. The plasma and brain tissue concentrations over time of (2S,6S)-hydroxynorketamine were determined after intravenous (20 mg/kg) and oral (20 mg/kg) administration of (2S,6S)-hydroxynorketamine (n = 3). After intravenous administration, the pharmacokinetic parameters were estimated using noncompartmental analysis and the half-life of drug elimination during the terminal phase (t(1/2)) was 8.0 ± 4.0 h and the apparent volume of distribution (V(d)) was 7352 ± 736 mL/kg, clearance (Cl) was 704 ± 139 mL/h per kg, and the bioavailability was 46.3%. Significant concentrations of (2S,6S)-hydroxynorketamine were measured in brain tissues at 10 min after intravenous administration, ∼30 μg/mL per g tissue which decreased to 6 μg/mL per g tissue at 60 min. The plasma and brain concentrations of (2S,6S)-hydroxynorketamine were also determined after the intravenous administration of (S)-ketamine, where significant plasma and brain tissue concentrations of (2S,6S)-hydroxynorketamine were observed 10 min after administration. The (S)-ketamine metabolites (S)-norketamine, (S)-dehydronorketamine, (2S,6R)-hydroxynorketamine, (2S,5S)-hydroxynorketamine and (2S,4S)-hydroxynorketamine were also detected in both plasma and brain tissue. The enantioselectivity of the conversion of (S)-ketamine and (R)-ketamine to the respective (2,6)-hydroxynorketamine metabolites was also investigated over the first 60 min after intravenous administration. (S)-Ketamine produced significantly greater plasma and brain tissue concentrations of (2S,6S)-hydroxynorketamine relative to the (2R,6R)-hydroxynorketamine observed after the administration of (R)-ketamine. However, the relative brain tissue: plasma concentrations of the enantiomeric (2,6)-hydroxynorketamine metabolites were not significantly different indicating that the penetration of the metabolite is not enantioselective.
format Online
Article
Text
id pubmed-4492732
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-44927322015-07-13 The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats Moaddel, Ruin Sanghvi, Mitesh Dossou, Katina Sourou Sylvestre Ramamoorthy, Anuradha Green, Carol Bupp, James Swezey, Robert O’Loughlin, Kathleen Wainer, Irving W Pharmacol Res Perspect Original Articles The distribution, clearance, and bioavailability of (2S,6S)-hydroxynorketamine has been studied in the Wistar rat. The plasma and brain tissue concentrations over time of (2S,6S)-hydroxynorketamine were determined after intravenous (20 mg/kg) and oral (20 mg/kg) administration of (2S,6S)-hydroxynorketamine (n = 3). After intravenous administration, the pharmacokinetic parameters were estimated using noncompartmental analysis and the half-life of drug elimination during the terminal phase (t(1/2)) was 8.0 ± 4.0 h and the apparent volume of distribution (V(d)) was 7352 ± 736 mL/kg, clearance (Cl) was 704 ± 139 mL/h per kg, and the bioavailability was 46.3%. Significant concentrations of (2S,6S)-hydroxynorketamine were measured in brain tissues at 10 min after intravenous administration, ∼30 μg/mL per g tissue which decreased to 6 μg/mL per g tissue at 60 min. The plasma and brain concentrations of (2S,6S)-hydroxynorketamine were also determined after the intravenous administration of (S)-ketamine, where significant plasma and brain tissue concentrations of (2S,6S)-hydroxynorketamine were observed 10 min after administration. The (S)-ketamine metabolites (S)-norketamine, (S)-dehydronorketamine, (2S,6R)-hydroxynorketamine, (2S,5S)-hydroxynorketamine and (2S,4S)-hydroxynorketamine were also detected in both plasma and brain tissue. The enantioselectivity of the conversion of (S)-ketamine and (R)-ketamine to the respective (2,6)-hydroxynorketamine metabolites was also investigated over the first 60 min after intravenous administration. (S)-Ketamine produced significantly greater plasma and brain tissue concentrations of (2S,6S)-hydroxynorketamine relative to the (2R,6R)-hydroxynorketamine observed after the administration of (R)-ketamine. However, the relative brain tissue: plasma concentrations of the enantiomeric (2,6)-hydroxynorketamine metabolites were not significantly different indicating that the penetration of the metabolite is not enantioselective. John Wiley & Sons, Ltd 2015-08 2015-06-22 /pmc/articles/PMC4492732/ /pubmed/26171236 http://dx.doi.org/10.1002/prp2.157 Text en © 2015 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Moaddel, Ruin
Sanghvi, Mitesh
Dossou, Katina Sourou Sylvestre
Ramamoorthy, Anuradha
Green, Carol
Bupp, James
Swezey, Robert
O’Loughlin, Kathleen
Wainer, Irving W
The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats
title The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats
title_full The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats
title_fullStr The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats
title_full_unstemmed The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats
title_short The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats
title_sort distribution and clearance of (2s,6s)-hydroxynorketamine, an active ketamine metabolite, in wistar rats
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492732/
https://www.ncbi.nlm.nih.gov/pubmed/26171236
http://dx.doi.org/10.1002/prp2.157
work_keys_str_mv AT moaddelruin thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT sanghvimitesh thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT dossoukatinasourousylvestre thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT ramamoorthyanuradha thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT greencarol thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT buppjames thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT swezeyrobert thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT oloughlinkathleen thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT wainerirvingw thedistributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT moaddelruin distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT sanghvimitesh distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT dossoukatinasourousylvestre distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT ramamoorthyanuradha distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT greencarol distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT buppjames distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT swezeyrobert distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT oloughlinkathleen distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats
AT wainerirvingw distributionandclearanceof2s6shydroxynorketamineanactiveketaminemetaboliteinwistarrats